The Conversation (0)
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the safety and clinical effectiveness of the investigational compound volasertib* in the treatment of hematologic malignancies.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the safety and clinical effectiveness of the investigational compound volasertib* in the treatment of hematologic malignancies.
According to Diane E. Paul, MS, RN, Vice President of NCCN ORP:
The ongoing collaboration between the NCCN ORP and Boehringer Ingelheim Pharmaceuticals is a true testament to the advancement of oncology research. This grant will afford investigators at NCCN Member Institutions the ability to be at the forefront of groundbreaking clinical research in hematologic malignancies.
Click here to read the full release.